- Investing Ideas
- Swiss Pharmaceuticals & Biotech High Return On Equity, Low Debt
Swiss Pharmaceuticals & Biotech High Return On Equity, Low Debt
Results
2
0 new
Stocks with a return on equity of over 30% and a debt to equity ratio below 1.
2 companies
Roche Holding
Market Cap: CHF 262.8b
Engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand.
ROP
CHF 329.30
7D
-1.6%
1Y
24.0%
Basilea Pharmaceutica
Market Cap: CHF 645.8m
A Swiss commercial-stage biotech company focused on developing and commercializing treatments for severe bacterial and fungal infections.
BSLN
CHF 52.10
7D
-2.3%
1Y
15.4%